Synergy between scientific advancement and technological innovation, illustrated by a mechanism-based model characterizing sodiumg-glucose cotransporter-2 inhibition

Journal of Clinical Pharmacology

Volumn 50, Issue 9, 2010, Pages

  Zhang, Liping ^a   Ng, Chee M ^b   List, James F ^a   Pfister, Marc ^a  

^a BRISTOL MYERS SQUIBB   (United States)

^b CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

diabetes; mechanism based modeling; Scientific advancement; SGLT2; technological innovation

Indexed keywords

ANTIDIABETIC AGENT; GLUCOSE; HEMOGLOBIN A1C; SODIUM GLUCOSE COTRANSPORTER 2; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; UNCLASSIFIED DRUG;

APPETITE; BIOTECHNOLOGY; COMPUTER ANALYSIS; COMPUTER PROGRAM; DRUG EFFICACY; DRUG TARGETING; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; INSULIN RELEASE; INSULIN SENSITIVITY; KIDNEY FUNCTION; METABOLIC RATE; NON INSULIN DEPENDENT DIABETES MELLITUS; REVIEW; SCIENCE;

DIABETES MELLITUS, TYPE 2; DRUG DELIVERY SYSTEMS; HUMANS; HYPOGLYCEMIC AGENTS; MODELS, BIOLOGICAL; SODIUM-GLUCOSE TRANSPORTER 2; TECHNOLOGY, PHARMACEUTICAL;

EID: 78449300025     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270010376974     Document Type: Review

References (39)

1. Drews J. Drug discovery today-and tomorrow. Drug Discov Today. 2000 ; 5: 2-4.
2. Drews J. Drug discovery: a historical perspective. Science. 2000 ; 287: 1960-1964.
3. Friedman LM Fundamentals of Clinical Trials. 4 th ed. New York, NY: Springer ; 2010.
4. Spilker B. Guide to Drug Development: A Comprehensive Review & Assessment. 1 st ed. Baltimore, Md: Lippincott Williams & Wilkins ; 2008.
5. Sheiner LB Learning versus confirming in clinical drug development. Clin Pharmacol Ther. 1997 ; 61: 275-291.
6. Berger JO Statistical Decision Theory and Bayesian Analysis. 2 nd ed. New York, NY: Springer-Verlag ; 1985.
7. Brigandt I., Love A. Reductionism in biology. 2008. http://plato. stanford.edu/entries/reduction-biology/. Accessed April 20, 2010.
8. Sauer U., Heinemann M., Zamboni N. Genetics. Getting closer to the whole picture. Science. 2007 ; 316: 550-551.
9. Davidov E., Holland J., Marple E., Naylor S. Advancing drug discovery through systems biology. Drug Discov Today. 2003 ; 8: 175-183.
10. Wright EM Renal Na(+)-glucose cotransporters. Am J Physiol Renal Physiol. 2001 ; 280: F10 - F18.
11. Marsenic O. Glucose control by the kidney: an emerging target in diabetes. Am J Kidney Dis. 2009 ; 53: 875-883.
12. List JF, Woo V., Morales E., Tang W., Fiedorek FT Sodium- glucose co-transport inhibition with dapagliflozin in type 2 diabetes mellitus. Diabetes Care. 2008 ; 32: 650-657.
13. Defronzo RA Banting lecture: from the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes. 2009 ; 58: 773-795.
14. Isaji M. Sodium-glucose cotransporter inhibitors for diabetes. Curr Opin Invest Drugs. 2007 ; 8: 285-292.
15. Cobelli C., Toffolo GM, Dalla Man C., et al. Assessment of beta-cell function in humans, simultaneously with insulin sensitivity and hepatic extraction, from intravenous and oral glucose tests. Am J Physiol Endocrinol Metab. 2007 ; 293: E1 - E15.
16. Jauslin PM, Silber HE, Frey N., et al. An integrated glucose-insulin model to describe oral glucose tolerance test data in type 2 diabetics. J Clin Pharmacol. 2007 ; 47: 1244-1255.
17. Silber HE, Jauslin PM, Frey N., Gieschke R., Simonsson US, Karlsson MO An integrated model for glucose and insulin regulation in healthy volunteers and type 2 diabetic patients following intravenous glucose provocations. J Clin Pharmacol. 2007 ; 47: 1159-1171.
18. Radziuk J., Pye S. Diurnal rhythm in endogenous glucose production is a major contributor to fasting hyperglycaemia in type 2 diabetes: suprachiasmatic deficit or limit cycle behaviour ? Diabetologia. 2006 ; 49: 1619-1628.
19. Beal B., Sheiner L. NONMEM User's Guide, Part I. San Francisco, Calif: University of California at San Francisco ; 1998.
20. Lavielle M., Mentre F. Estimation of population pharmacokinetic parameters of saquinavir in HIV patients with the MONOLIX software. J Pharmacokinet Pharmacodyn. 2007 ; 34: 229-249.
21. Davidian M., Giltinan DM Nonlinear Models for Repeated Measures Data. New York, NY: Chapman & Hall ; 1995.
22. Bauer RJ, Guzy S. Monte Carlo parametric expectation maximization (MC-PEM) method for analyzing population pharmacokinetic/pharmacodynamic (PK/PD) data. In: D'Argenio DZ, ed. Advanced Methods of Pharmacokinetic and Pharmacodynamic System Analysis. Boston, Mass: Kluwer Academic ; 2004: 135-163.
23. Bauer RJ, Guzy S., Ng C. A survey of population analysis methods and software for complex pharmacokinetic and pharmacodynamic models with examples. AAPS J. 2007 ; 9: E60 - E83.
24. Walker S. An EM algorithm for nonlinear random effects models. Biometrics. 1996 ; 52: 934-944.
25. Schumitzky A. EM algorithms and two stage methods in pharmacokinetic population analysis. In: D'Argenio DZ, ed. Advanced Methods of Pharmacokinetic and Pharmacodynamic System Analysis. New York, New York: Plenum Press ; 1995: 145-160.
26. Ng CM, Joshi A., Dedrick RL, Garovoy MR, Bauer RJ Pharmacokinetic- pharmacodynamic-efficacy analysis of efalizumab in patients with moderate to severe psoriasis. Pharm Res. 2005 ; 22: 1088-1100.
27. Ng C., Bauer R. The use of beowulf cluster to accelerate the performance of Monte-Carlo parametric expectation maximization (MCPEM) algorithm in analyzing complex population pharmacokinetic/pharmacodynamic/efficacy data. Clin Pharmacol Ther. 2006 ; 79: P54.
28. Rossetti L., Smith D., Shulman GI, Papachristou D., DeFronzo RA Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats. J Clin Invest. 1987 ; 79: 1510-1515.
29. Rossetti L., Shulman GI, Zawalich W., DeFronzo RA Effect of chronic hyperglycemia on in vivo insulin secretion in partially pancreatectomized rats. J Clin Invest. 1987 ; 80: 1037-1044.
30. Monnier L., Colettie C. Target for glycemic control: concentrating on glucose. Diabetes Care. 2009 ; 32: S199 - S204.
31. Rave K., Nosek L., Posner J., Heise T., Roggen K., van Hoogdalem EJ Renal glucose excretion as a function of blood glucose concentration in subjects with type 2 diabetes-results of a hyperglycaemic glucose clamp study. Nephrol Dial Transplant. 2006 ; 21: 2166-2171.
32. Center for Drug Evaluation and Research. Innovation or Stagnation: Challenge and Opportunity on the Critical Path to New Medical Products. Rockville, Md: U.S. Food and Drug Administration ; 2004.
33. Bhattaram VA, Booth BP, Ramchandani RP, et al. Impact of pharmacometrics on drug approval and labeling decisions: a survey of 42 new drug applications. AAPS J. 2005 ; 7: E503 - E512.
34. Powell JR, Gobburu JV Pharmacometrics at FDA: evolution and impact on decisions. Clin Pharmacol Ther. 2007 ; 82: 97-102.
35. Suryawanshi S., Zhang L., Pfister M., Meibohm B., Healthcare PI The current role of model-based drug development. Expert Opin Drug Discov. 2010 ; 5: 311-321.
36. Zhang L., Pfister M., Meibohm B. Concepts and challenges in quantitative pharmacology and model-based drug development. AAPS J. 2008 ; 10: 552-559.
37. Silverman M., Turner RJ Renal physiology. In: Windhager EE, (editor), Handbook of Physiology. 5 th ed. New York, NY: Oxford University Press ; 1992: 2017-2038.
38. Jabbour SA, Goldstein BJ Sodium glucose co-transporter 2 inhibitors: blocking renal tubular reabsorption of glucose to improve glycaemic control in patients with diabetes. Int J Clin Pract. 2008 ; 62: 1279-1284.
39. DeFronzo RA Current issues in the treatment of type 2 diabetes: overview of newer agents: where treatment is going. Am J Med. 2010 ; 123 (3 suppl). S38 - S48.